Paper · 36498473
References96
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
1 to 20 of 96
Download this page as JSON| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33,292,582 | The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome. | J Intensive Care | 2020 | https://conductscience.org/library/papers/33292582 | PubMed |
| 2 | 10,990,106 | Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. | Intensive Care Med | 2000 | https://conductscience.org/library/papers/10990106 | PubMed |
| 3 | 21,333,028 | Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. | BMC Anesthesiol | 2011 | https://conductscience.org/library/papers/21333028 | PubMed |
| 4 | 19,397,464 | Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. | Pharmacotherapy | 2009 | https://conductscience.org/library/papers/19397464 | PubMed |
| 5 | 23,642,005 | Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? | Crit Care | 2013 | https://conductscience.org/library/papers/23642005 | PubMed |
| 6 | 27,451,086 | Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. | Int J Antimicrob Agents | 2016 | https://conductscience.org/library/papers/27451086 | PubMed |
| 7 | 30,626,244 | Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. | Expert Opin Drug Metab Toxicol | 2019 | https://conductscience.org/library/papers/30626244 | PubMed |
| 8 | 28,571,493 | Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? | Expert Rev Anti Infect Ther | 2017 | https://conductscience.org/library/papers/28571493 | PubMed |
| 9 | 31,358,583 | Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/31358583 | PubMed |
| 10 | 24,768,475 | Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. | Lancet Infect Dis | 2014 | https://conductscience.org/library/papers/24768475 | PubMed |
| 11 | 28,158,470 | Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/28158470 | PubMed |
| 12 | 16,355,321 | The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. | Clin Infect Dis | 2006 | https://conductscience.org/library/papers/16355321 | PubMed |
| 13 | 34,224,115 | Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Adults During Extracorporeal Membrane Oxygenation: A Systematic Review. | Drugs | 2021 | https://conductscience.org/library/papers/34224115 | PubMed |
| 14 | 31,325,141 | What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/31325141 | PubMed |
| 15 | 34,034,594 | Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits. | Perfusion | 2022 | https://conductscience.org/library/papers/34034594 | PubMed |
| 16 | 27,012,450 | Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy. | Pharmacotherapy | 2016 | https://conductscience.org/library/papers/27012450 | PubMed |
| 17 | 15,656,698 | Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. | Clin Pharmacokinet | 2005 | https://conductscience.org/library/papers/15656698 | PubMed |
| 18 | 34,250,190 | Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration. | Open Forum Infect Dis | 2021 | https://conductscience.org/library/papers/34250190 | PubMed |
| 19 | 20,862,453 | Determinants of drug absorption in different ECMO circuits. | Intensive Care Med | 2010 | https://conductscience.org/library/papers/20862453 | PubMed |
| 20 | 23,683,557 | Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. | J Crit Care | 2013 | https://conductscience.org/library/papers/23683557 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/36498473/references